Faster, Smarter Drug Discovery
At Delta4, we combine systems biology, computational modeling, AI, and large-scale data to understand disease mechanisms, discover new therapeutic targets, and predict drug behavior in silico — accelerating every stage of drug development with precision and speed.
Delta4 is a TechBio company focused on helping clients expand indications for existing drugs with known safety profiles.
We accelerate new treatment options to improve the health of patients and get them into their hands faster, more safely, and more efficiently than traditional approaches.
We’re proud to share that Delta4 has been featured by the Austrian Research Promotion Agency (FFG) for our work advancing computational biology. At Delta4, we connect expertise, foster young talent, and leverage data-driven innovation to improve patient outcomes.
We help our clients discover undetected relationships between drugs with a known safety profile to identify new indications.
We do this by leveraging Hyper-C, our proprietary artificial intelligence powered platform that allows us to detect these relationships with unprecedented speed, accuracy, and efficiency.
Hyper-C is operated by our team of highly skilled computational biologists who carefully analyze the data to produce unique insights and detect drug indication expansion opportunities.
The results are new therapeutic options that find their way to market faster, more cost-effectively than ever before.
Apply our in-silico models to accelerate your drug or indication program.
Explore how systems biology and AI power our predictive platform.
Collaborate with us on research, co-development, or consortia projects.
It’s an honor and a privilege to be working with the best of the best!
Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.
“Delta4’s AI-Powered Hyper-C Platform Uncovers New Drug Indications, Expanding Treatment Potential for Iguratimod” – As Featured on Scientist.com
